Meta-Analysis of Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil Chemotherapy in Postmenopausal Women with Estrogen Receptor–Positive, Node-Positive Breast Cancer

This publication has 18 references indexed in Scilit:

• Tamoxifen for early breast cancer: an overview of the randomised trials
  The Lancet, 1998
• Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
  Journal of Clinical Oncology, 1997
• Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
  Journal of Clinical Oncology, 1997
• The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up
  Annals of Oncology, 1994
• Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (breast cancer adjuvant chemo-hormone therapy cooperative group) trial
  European Journal Of Cancer, 1992
• A general parametric approach to the meta‐analysis of randomized clinical trials
  Statistics in Medicine, 1991
• Endocrineversus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer
  Cancer, 1989
• Meta-analysis in clinical trials
  Controlled Clinical Trials, 1986
• Dose-Response Effect of Adjuvant Chemotherapy in Breast Cancer
  New England Journal of Medicine, 1981
• Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients
  British Journal of Cancer, 1980